BACKGROUND: Effective anti-inflammatory treatment with tumour necrosis factor α (TNFα) inhibitors may have favourable effects on the lipid profile. Available evidence is derived from short-term studies, and it is not clear whether TNFα inhibitors have a similar effect on the lipid profile in responders and non-responders to the treatment. OBJECTIVES: To investigate the effect of long-term etanercept treatment on the lipid profile in a large sample of patients with rheumatoid arthritis (RA), stratified for European League Against Rheumatism (EULAR) response. METHODS: Between 2004 and 2008, 292 consecutive patients with active RA (DAS28 >3.2) and a new etanercept prescription were included in an observational cohort. Clinical response variables and lipid samples were collected at baseline and after 4 months and 1 year of etanercept treatment. Generalised estimating equation analyses were used to investigate the longitudinal course of lipid levels in relation to clinical response variables. RESULTS: According to the EULAR response criteria, 76% of the patients were good or moderate responders at 4 months, and 85% of the remainder at 1 year. Significant changes in apoA-I (increased by 3.5% (p=0.002) at 4 months and 3.1% (p=0.005) at 1 year) and apoB/apoA-I ratio (decreased by 6.2% (p<0.001) at 4 months and 3.6% (p=0.025) at 1 year) were observed in EULAR responders. No significant differences were observed in EULAR non-responders at all time points. CONCLUSIONS: Treatment with etanercept resulted in a significant and sustained decrease in the apoB/apoA-I ratio in patients with good or moderate EULAR response. This may have a beneficial effect on the cardiovascular risk in patients with RA.
BACKGROUND: Effective anti-inflammatory treatment with tumour necrosis factor α (TNFα) inhibitors may have favourable effects on the lipid profile. Available evidence is derived from short-term studies, and it is not clear whether TNFα inhibitors have a similar effect on the lipid profile in responders and non-responders to the treatment. OBJECTIVES: To investigate the effect of long-term etanercept treatment on the lipid profile in a large sample of patients with rheumatoid arthritis (RA), stratified for European League Against Rheumatism (EULAR) response. METHODS: Between 2004 and 2008, 292 consecutive patients with active RA (DAS28 >3.2) and a new etanercept prescription were included in an observational cohort. Clinical response variables and lipid samples were collected at baseline and after 4 months and 1 year of etanercept treatment. Generalised estimating equation analyses were used to investigate the longitudinal course of lipid levels in relation to clinical response variables. RESULTS: According to the EULAR response criteria, 76% of the patients were good or moderate responders at 4 months, and 85% of the remainder at 1 year. Significant changes in apoA-I (increased by 3.5% (p=0.002) at 4 months and 3.1% (p=0.005) at 1 year) and apoB/apoA-I ratio (decreased by 6.2% (p<0.001) at 4 months and 3.6% (p=0.025) at 1 year) were observed in EULAR responders. No significant differences were observed in EULAR non-responders at all time points. CONCLUSIONS: Treatment with etanercept resulted in a significant and sustained decrease in the apoB/apoA-I ratio in patients with good or moderate EULAR response. This may have a beneficial effect on the cardiovascular risk in patients with RA.
Authors: Cynthia S Crowson; Katherine P Liao; John M Davis; Daniel H Solomon; Eric L Matteson; Keith L Knutson; Mark A Hlatky; Sherine E Gabriel Journal: Am Heart J Date: 2013-08-29 Impact factor: 4.749
Authors: Christina Charles-Schoeman; Xiaoyan Wang; Yuen Yin Lee; Ani Shahbazian; Iris Navarro-Millán; Shuo Yang; Lang Chen; Stacey S Cofield; Larry W Moreland; James O'Dell; Joan M Bathon; Harold Paulus; S Louis Bridges; Jeffrey R Curtis Journal: Arthritis Rheumatol Date: 2016-03 Impact factor: 10.995
Authors: Iris Navarro-Millán; Christina Charles-Schoeman; Shuo Yang; Joan M Bathon; S Louis Bridges; Lang Chen; Stacey S Cofield; Louis J Dell'Italia; Larry W Moreland; James R O'Dell; Harold E Paulus; Jeffrey R Curtis Journal: Arthritis Rheum Date: 2013-06
Authors: J C van Denderen; G J Blom; I E van der Horst-Bruinsma; B A C Dijkmans; M T Nurmohamed Journal: Clin Rheumatol Date: 2012-09-01 Impact factor: 2.980
Authors: Rishi J Desai; Wesley Eddings; Katherine P Liao; Daniel H Solomon; Seoyoung C Kim Journal: Arthritis Care Res (Hoboken) Date: 2015-04 Impact factor: 4.794